menu toggle

Catch up on the latest global health technology assessment (HTA) news and browse our past issues.

HTA Quarterly Archive

Global map

HTA Quarterly

Spring 2024

In this edition, we continue our series on preparing for the introduction of European Union (EU) health technology assessment (HTA), consider how United States (US) drug pricing negotiations under the Inflation Reduction Act (IRA) compare with those in countries with an established price negotiation framework, and assess the strengths and limitations of artificial intelligence (AI) tools for literature reviews.

HTA Quarterly

Winter 2023

With EUnetHTA 21 coming to an end and details emerging of the timelines and evidence requirements that will govern the new Joint Scientific Consultation (JSC) and Joint Clinical Assessment (JCA) processes, the authors consider how biopharma companies, health technology assessment (HTA) bodies, patients, and clinicians can best prepare for the start of the European Health Technology Assessment Regulation (HTAR). Also in this edition, we review the latest changes to the Institute for Clinical and Economic Review (ICER)’s value assessment framework, and explore the National Institute for Health and Care Excellence (NICE)’s early value assessment approach to assessing MedTech, including digital health technologies.

HTA Quarterly

Fall 2023

With just 17 months until Joint Clinical Assessment (JCA) is implemented for oncology drugs and advanced therapy medicinal products (ATMPs) in the European Union, in this edition we consider what we know so far and what is still uncertain. The authors also reflect on the industry’s perception of the current UK Voluntary Pricing and Access Scheme and hopes for the new scheme scheduled to start in January 2024. Against the backdrop of increased payer interest in and use of US value assessment tools, we question whether ICER’s assessment framework is sufficiently rigorous to accurately capture the value of potentially transformational therapies.

HTA Quarterly

Summer 2023

Marking the 10th anniversary of HTA Quarterly, the editors reflect on the ever-changing face of market access, as biopharma companies, regulators, and payers unite in a common aim to improve outcomes for patients while directing funds to those products that offer the greatest value. We also look back at the first 3 years of Project Orbis, a collaborative program intended to standardize and streamline global approval of innovative oncology treatments, and consider the role of artificial intelligence in the future of HTA.

HTA Quarterly

Spring 2023

In this issue, our editors examine assessment of innovation in Italy; while the rules may be clear, the outcomes are not always black and white. Additionally, in a pair of articles focused on the rapidly growing biosimilars market, we consider the market dynamics and incentives that impact biosimilar adoption, pricing, and reimbursement, in both the US and Europe.

HTA Quarterly

Winter 2022

In this issue, our editors examine how the new Innovative Medicines Fund offers a faster route to market for promising non-cancer drugs in the UK, learnings from the first 5 years with the Danish Medicines Council, and implications of the US’s new drug pricing law.

HTA Quarterly

Fall 2022

In this issue, our editors provide insights on the new European Union health technology assessment (HTA) regulation, an analysis of the use of health economics to respond to the COVID-19 pandemic, and a review of Germany’s newly adopted Statutory Health Insurance Financial Stabilization Act.

HTA Quarterly

Summer 2022

In this issue, our editors provide insights on the Institute for Clinical and Economic Review’s (ICER’s) recently published assessment of fair access criteria, a review of the lock system for orphan drugs in the Netherlands, and an analysis of the United Kingdom (UK) National Institute for Health and Care Excellence’s (NICE’s) new Health Technology Assessment (HTA) manuals. 

HTA Quarterly

Spring 2022

In this issue our editors provide insights on the new European Union Health Technology Assessment regulation, the United Kingdom's Innovative Licensing and Access Pathway, and the drug reimbursement environment in Canada.

HTA Quarterly

Winter 2021

In this issue, we examine NICE's 5-year strategy and their focus on collaborative engagement, the German assessment process for digital health applications and the importance of prospective studies, and the use of telehealth in value-based care models.

HTA Quarterly

Fall 2021

In this issue, our editors examine ICER's approach to Unsupported Price Increase (UPI) assessments, how health disparities play a pivotal role in health outcomes of marginalized patient populations, and how the evolution of cancer therapeutics offers opportunities to gain insights from key opinion leaders in oncology.

HTA Quarterly

Winter 2020

In this issue, our editors examine ICER's growing influence payer decisions making, subscription-based antibiotic programs, and the path into the German healthcare market for advanced therapy medicinal products.

HTA Quarterly 

Summer 2021

In this issue, our editors examine two new tools from the Institute for Clinical and Economic Review (ICER), assess the value of vaccines from an HTA perspective, and provide an update from our previously published infectious disease economic model on the COVID-19 pandemic.

HTA Quarterly

Spring 2021

In this issue, our editors examine how real-world evidence impacts regulatory decisions in the United States, the current state of reimbursement for Advanced Therapy Medicinal Products (ATMPs) in Germany, and a look at two value assessment frameworks Innovation and Value Initiative (IVI) and the Institute for Clinical and Economic Review (ICER).


Fall 2020

In this issue, our editors examine market access in South Korea, new treatments for Alzheimer's disease, new policies in China, and the patient role in ICER value assessments.

HTA Quarterly

Summer 2020

In this issue, our editors examine digital health technology (DHT) from a global perspective, the value drivers for emerging gene therapies for hemophilia, and the impact of the European Union’s new medical devices guidance on DHTs.

HTA Quarterly

Spring 2020

In this issue, our editors examine the patient voice and HTA, updates to the ICER and NICE frameworks, and the changing healthcare landscape in India with the adoption of their own HTA.

HTA Quarterly

Fall 2019

In this issue, our editors examine cost-effectiveness assessments for innovative but high-cost treatments, market access for cell and gene therapies in key European countries, and newest joint HTA assessments, FINOSE.

HTA Quarterly

Summer 2019

In this issue, we review HTA frameworks for next-gen sequencing in precision oncology, how HTAs review tumor-agnostic therapies, and the rise of complex technologies and their reimbursement landscape. Read our special feature, Hot Topic, on the changes in France’s healthcare system on medicinal products.

HTA Quarterly

Spring 2019

In this issue, we examine the impact of the 21st Century Cures Act on stakeholders in the United States, explore the proposed rule from the Centers for Medicare & Medicaid Services on managed care value-based formulary decisions, and consider how patient input can help influence drug development.

HTA Quarterly

Winter 2019

In this issue, we take a closer look at the utilization of “multiple criteria decision analysis” (MCDA) in health technology appraisals, newer therapies for Cystic Fibrosis, and the regulatory pathways and complexity of health technology assessment (HTA) evidentiary hurdles for new diabetes drugs, devices, and combination technologies.

HTA Quarterly

Fall 2018

We examine wearable technology and big data, valuing CAR-T therapies, and a look at Catalonia and the region's autonomous healthcare market.

HTA Quarterly

Late Summer 2018

We examine the world's second largest pharmaceuticals market as Japan shifts from a traditional reimbursement assessment. We look at new therapies for Tardive Dyskinesea. We also review Taiwan's Center for Drug Evaluation on its 10 year anniversary.

HTA Quarterly

Summer 2018

We take a look at whether value frameworks are the path to implementing value-based pricing, the EMA's move out of the United Kingdom, and look at the health policy trends in Canada from InnomarLive.

HTA Quarterly 

Spring 2018

We examine oncology appraisal differences between NICE and SMC, market access for cell and gene therapies, and managed entry agreements.

HTA Quarterly

Late Summer 2017

We examine medical nutrition reimbursement, severe asthma therapies, and brazil's healthcare market.


Summer 2017

We take a look at patient input into HTA decisions in 4 countries, examining new therapies for Duchenne Muscular Dystrophy, and understanding the Colombian universal healthcare model.


Spring 2017

We examine the process to appeal unfavorable NICE decisions, provide insights on immunotherapy coverage and reimbursement, and take a deeper look at global value dossiers.

HTA Quarterly

Winter 2017

We examine indication-specific pricing in Europe and in the US, approved therapies for multiple myeloma, and take a closer look at Portugal's HTA body, SiNATS.

HTA Quarterly

Fall 2016

We examine rapid access in the US, UK, and France, targeted therapies for psoriasis and psoriatic arthritis, and explore Singapore's highly efficient healthcare system.

Our editors



Kellie Meyer, PharmD, MPH

Vice President, Evidence Generation & Value Communications

Thomas Mittendorf


Thomas Mittendorf, PhD, MSc

Thomas Mittendorf

Vice President, Real-World Evidence & HTA Support

Thomas Mittendorf

Managing editor

Jayne Hurrell, MA

Director, Value & Access Communication

Editorial board

  • Tommy Bramley, PhD

    Sr. Vice President | Global Consulting | United Kingdom 

  • Josep Darbà, PhD

    Professor | Department of Economics | University of Barcelona | Spain

  • Grant Perry, BPA(h)

    Sr. Director | Innomar Strategies | Canada

  • Mike Drummond, PhD

    Professor | Centre for Health Economics | University of York | United Kingdom

  • George Papadopoulos, BSc(Hons), GradDipEpi

    Director & Partner | Lucid Health Consulting | Australia

  • Ken Redekop, PhD  
    Associate Professor I Erasmus University I The Netherlands
  • Eldon Spackman, BA, MA, PhD 
    Co-Director | Institute for Public Health | University of Calgary | Canada
  • Keith Tolley, BA, MPhil 
    Director | Tolley Health Economics | United Kingdom